Source-first knowledge base

Daraxon research library

A compact index of primary regulatory records, compound data, clinical trials and peer-reviewed evidence for daraxonrasib / RMC-6236.

Editorial standard

Trace every important statement back to a source.

Medical and regulatory information changes. We prioritize FDA, NCBI, ClinicalTrials.gov and original peer-reviewed publications, show review dates on medical explainers and separate Daraxon product statements from independently published evidence.

Development programs

Revolution Medicines · RAS(ON) G12D

Zoldonrasib / RMC-9805

Developer information on zoldonrasib, an oral RAS(ON) G12D-selective inhibitor.

Open primary source

Tango Therapeutics · PRMT5

Vopimetostat / TNG462

Developer overview of the MTA-cooperative PRMT5 program in MTAP-deleted cancers.

Open primary source

Regulatory

U.S. FDA · 26 August 2026

FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

Official approval notice identifying RASONQUE, its active ingredient, sponsor and approved population.

Open primary source

U.S. FDA · current list

2026 Novel Drug Approvals

FDA’s annual list records Rasonque (daraxonrasib) and the approval date.

Open primary source

U.S. FDA · quarterly list

List of Drug Master Files

Official quarterly DMF records. The 2026 Q2 list includes Daraxonrasib 43871, Zoldonrasib 44304 and Vopimetostat 44318.

Open primary source

Compound identity

PubChem CID 164726578 · NCBI

Daraxonrasib compound record

Chemical formula, molecular weight, CAS identifier, structure and synonyms.

Open primary source

Peer-reviewed evidence

Science · 2023 · PMID 37590355

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Foundational work describing the active-state RAS tri-complex strategy.

Open primary source

Cancer Discovery · 2024 · DOI 10.1158/2159-8290.CD-24-0027

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236

Preclinical characterization and initial clinical translation of RMC-6236.

Open primary source

New England Journal of Medicine · 2026 · PMID 42090791

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Phase 1–2 clinical report focused on previously treated RAS-mutated PDAC.

Open primary source

New England Journal of Medicine · 2026 · PMID 42223072

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

Peer-reviewed phase 3 RASolute 302 report.

Open primary source

Clinical trials

ClinicalTrials.gov · NCT05379985

RMC-6236-001

Study record for RMC-6236 in advanced solid tumors with specified RAS mutations.

Open primary source

ClinicalTrials.gov · NCT06625320

RASolute 302

Phase 3 record in previously treated metastatic pancreatic ductal adenocarcinoma.

Open primary source

Last reviewed14 September 2026

See something that needs correction or a newer primary source?

Send a source or correction →